Category: Zynex Inc.
Zynex touts FDA clearance for its InWave electrotherapy device for treating female urinary incontinence.
Colorado-based device maker Zynex (OTC:ZYXI) won FDA clearance for its InWave device, an electrotherapy system for treating female urinary incontinence.
The company's hoping that the InWave device will complement its existing electrotherapy portfolio and spur a boost in revenue, CEO Thomas Sandgaard said in a press release.
Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year; plus, Q1 sales, earnings up for Henry Schein; LeMaitre Vascular's Q1 profits soar; Mindray's Q1 profits slide despite double-digit sales boost; Stereotaxis boosts Q1 sales, slashes losses; Steris profits spike in 2011; Symmetry Medical's Q1 bottom line plunges; Syneron boosts Q1 sales, losses widen; and more.
Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
Italian medical device maker Sorin Group posts flat sales for 2011, but boosts profits by more than 48%; also, Dräger Medical's 2011 sales dip 2%; Sanuwave's 2011 sales rise, losses narrow; Aastrom's 2011 sales soar, losses mount; Sales tick up, profits soar for American Shared Hospital Services; Atrion's 2011 sales, profits rise; Sales rise, losses narrow for BioMimetic Therapeutics; InVivo Therapeutics' losses rise 340%; Sales, earnings up for Synergetics during Q2; Utah Medical's sales rise more than 50% in 2011; and Zynex logs 2011 profit growth of 347%.
Sorin Group (BIT:SRN) reported flat sales but strong profit growth for 2011, saying it raised earnings by 48.3% and revealing that the cardiac rhythm management slump has made its way across the pond.
The Italian medical device maker posted net income of €58.0 million (~$75.2 million) on sales of €743.4 million (~$963.4 million) for the year ended Dec. 31, 2011. That compares with profits of €39.1 million (~$50.7 million) on sales of €745.8 million (~$966.5 million) during 2010.
Standard & Poor's gives Medtronic's long-term debt an "A+" rating; also, ICU Medical to re-state financials; Zynex details NeuroDyne buyout terms; GI Dynamics dips on huge volume; Report: JPMorgan testing the waters for Kai Medical IPO; Delcath inks French training deal for Chemosat device; Misonix signs Asian distribution deal; Premier inks urological device deals; plus, a Funding Roundup and analysts' ups and downs.
Standard & Poor's Ratings Services affirmed Medtronic's (NYSE:MDT) long-term debt's "A+" rating yesterday, after the med-tech titan announced another debt offering.
The rating agency said its view of Medtronic's senior unsecured notes and its stable rating outlook "reflect the company's 'strong' business risk profile and 'modest' financial risk profile."
Masimo acquired the assets of Spire Semiconductor for an undisclosed amount, a move intended to cut costs and while facilitating development and innovation.
MASSDEVICE ON CALL — Masimo (NSDQ:MASI) nabbed light-emitting diode-maker Spire Semiconductor LLC for an undisclosed amount in a move aimed at cutting costs, speeding development and spurring innovation.
Spire's advanced LED technology was spun into a wholly owned Hudson, N.H.-based subsidiary named Masimo Semiconductor, which will develop custom components for Masimo's devices as well as for biomedical, telecommunications, consumer products and other markets, according to a press release.
The Massachusetts Life Sciences Center awards $2.2 million in loans to 3 Boston-area life sciences startups.
The Massachusetts Life Sciences Center awarded a total of $2.2 million in loans to 3 Boston-area life sciences startups - Allurion Technologies, Paragonix Technologies and Intelligent Bio-Systems.
The quasi-public agency's flagship Accelerator Program provides loans up to $750,000 to early-stage life sciences companies as a part of Massachusetts' 10 year, $1 billion Life Sciences Initiative.
A patent infringement lawsuit filed against Occlutech CEO Tor Peters by St. Jude is "amazing and quite shocking," according to Peters.
A patent spat between St. Jude Medical (NYSE:STJ) and Occlutech GmbH that morphed into a personal lawsuit against Occlutech CEO Tor Peters was dismissed by a German court, prompting Peters to call the suit "amazing and quite shocking."
St. Jude inherited the case, involving intravascular occlusion devices, after it acquired AGA Medical for more than $1 billion last year.